{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:17:08Z","timestamp":1776709028697,"version":"3.51.2"},"reference-count":58,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AIRC Fellowships Italy 2021","award":["Project code 26875"],"award-info":[{"award-number":["Project code 26875"]}]},{"name":"Associazione Italiana per la Ricerca sul Cancro","award":["IG N\u00b0 19822"],"award-info":[{"award-number":["IG N\u00b0 19822"]}]},{"DOI":"10.13039\/501100023296","name":"Alleanza Contro il Cancro","doi-asserted-by":"publisher","award":["RCR-2019 \u201323669120"],"award-info":[{"award-number":["RCR-2019 \u201323669120"]}],"id":[{"id":"10.13039\/501100023296","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,8,8]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Understanding how cancer signaling pathways promote an immunosuppressive program which sustains acquired or primary resistance to immune checkpoint blockade (ICB) is a crucial step in improving immunotherapy efficacy. Among the pathways that can affect ICB response is the interferon (IFN) pathway that may be both detrimental and beneficial. The immune sensor retinoic acid-inducible gene I (RIG-I) induces IFN activation and secretion and is activated by actin cytoskeleton disturbance. The actin cytoskeleton regulatory protein hMENA, along with its isoforms, is a key signaling hub in different solid tumors, and recently its role as a regulator of transcription of genes encoding immunomodulatory secretory proteins has been proposed. When hMENA is expressed in tumor cells with low levels of the epithelial specific hMENA<jats:sup>11a<\/jats:sup> isoform, identifies non-small cell lung cancer (NSCLC) patients with poor prognosis. Aim was to identify cancer intrinsic and extrinsic pathways regulated by hMENA<jats:sup>11a<\/jats:sup> downregulation as determinants of ICB response in NSCLC. Here, we present a potential novel mechanism of ICB resistance driven by hMENA<jats:sup>11a<\/jats:sup> downregulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Effects of hMENA<jats:sup>11a<\/jats:sup> downregulation were tested by RNA-Seq, ATAC-Seq, flow cytometry and biochemical assays. ICB-treated patient tumor tissues were profiled by Nanostring IO 360 Panel enriched with hMENA custom probes. OAK and POPLAR datasets were used to validate our discovery cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Transcriptomic and biochemical analyses demonstrated that the depletion of hMENA<jats:sup>11a<\/jats:sup> induces IFN pathway activation, the production of different inflammatory mediators including IFN\u03b2 <jats:italic>via<\/jats:italic> RIG-I, sustains the increase of tumor PD-L1 levels and activates a paracrine loop between tumor cells and a unique macrophage subset favoring an epithelial-mesenchymal transition (EMT). Notably, when we translated our results in a clinical setting of NSCLC ICB-treated patients, transcriptomic analysis revealed that low expression of hMENA<jats:sup>11a<\/jats:sup>, high expression of IFN target genes and high macrophage score identify patients resistant to ICB therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Collectively, these data establish a new function for the actin cytoskeleton regulator hMENA<jats:sup>11a<\/jats:sup> in modulating cancer cell intrinsic type I IFN signaling and extrinsic mechanisms that promote protumoral macrophages and favor EMT. These data highlight the role of actin cytoskeleton disturbance in activating immune suppressive pathways that may be involved in resistance to ICB in NSCLC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-006913","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T11:16:38Z","timestamp":1692789398000},"page":"e006913","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02008227","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01903993","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Paola","family":"Trono","sequence":"first","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"},{"name":"Institute of Biochemistry and Cell Biology, Consiglio Nazionale delle Ricerche, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Tocci","sequence":"additional","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Palermo","sequence":"additional","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Di Carlo","sequence":"additional","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9656-7436","authenticated-orcid":false,"given":"Lorenzo","family":"D'Ambrosio","sequence":"additional","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"D'Andrea","sequence":"additional","affiliation":[{"name":"Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Di Modugno","sequence":"additional","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"De Nicola","sequence":"additional","affiliation":[{"name":"SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frauke","family":"Goeman","sequence":"additional","affiliation":[{"name":"SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Corleone","sequence":"additional","affiliation":[{"name":"SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5046-2890","authenticated-orcid":false,"given":"Sarah","family":"Warren","sequence":"additional","affiliation":[{"name":"NanoString Technologies Inc, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Paolini","sequence":"additional","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Panetta","sequence":"additional","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, IRCSS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Baldari","sequence":"additional","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Visca","sequence":"additional","affiliation":[{"name":"Pathology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Carpano","sequence":"additional","affiliation":[{"name":"Second Division of Medical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Cappuzzo","sequence":"additional","affiliation":[{"name":"Second Division of Medical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Tripodo","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Human Pathology Section, Tumor Immunology Unit, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Zucali","sequence":"additional","affiliation":[{"name":"Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa","family":"Gregorc","sequence":"additional","affiliation":[{"name":"Department of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-5721","authenticated-orcid":false,"given":"Federica","family":"Marchesi","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy"},{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-2261","authenticated-orcid":false,"given":"Paola","family":"Nistico","sequence":"additional","affiliation":[{"name":"Tumor of Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"2025100312591176000_11.8.e006913.1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003956","article-title":"Society for Immunotherapy of cancer (SITC) clinical practice guideline on Immunotherapy for the treatment of lung cancer and Mesothelioma","volume":"10","author":"Govindan","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100312591176000_11.8.e006913.2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo3958","article-title":"Translating the evolving molecular landscape of tumors to biomarkers of response for cancer Immunotherapy","volume":"14","author":"Anagnostou","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025100312591176000_11.8.e006913.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.14"},{"key":"2025100312591176000_11.8.e006913.4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","article-title":"Type I Ifns promote cancer cell Stemness by triggering the epigenetic regulator Kdm1B","volume":"23","author":"Musella","year":"2022","journal-title":"Nat Immunol"},{"key":"2025100312591176000_11.8.e006913.5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127458"},{"key":"2025100312591176000_11.8.e006913.6","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"2025100312591176000_11.8.e006913.7","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-2431","article-title":"Activation of the IFN signaling pathway is associated with resistance to Cdk4\/6 inhibitors and immune Checkpoint activation in ER-positive breast cancer","volume":"27","author":"De Angelis","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025100312591176000_11.8.e006913.8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s43018-020-0048-0","article-title":"EGFR inhibition triggers an adaptive response by Co-opting antiviral signaling pathways in lung cancer","volume":"1","author":"Gong","year":"2020","journal-title":"Nat Cancer"},{"key":"2025100312591176000_11.8.e006913.9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-031920-093932"},{"key":"2025100312591176000_11.8.e006913.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.022"},{"key":"2025100312591176000_11.8.e006913.11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","article-title":"The interferon-stimulated gene Ripk1 regulates cancer cell intrinsic and Extrinsic resistance to immune Checkpoint blockade","volume":"55","author":"Cucolo","year":"2022","journal-title":"Immunity"},{"key":"2025100312591176000_11.8.e006913.12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41422-019-0224-x","article-title":"Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade","volume":"29","author":"Jacquelot","year":"2019","journal-title":"Cell Res"},{"key":"2025100312591176000_11.8.e006913.13","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011908","article-title":"Epithelial-Mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix Metalloproteinases","volume":"4","author":"Nistic\u00f2","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025100312591176000_11.8.e006913.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-008-9169-0"},{"key":"2025100312591176000_11.8.e006913.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2017.05.008"},{"key":"2025100312591176000_11.8.e006913.16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0603"},{"key":"2025100312591176000_11.8.e006913.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00541-7"},{"key":"2025100312591176000_11.8.e006913.18","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2010.195"},{"key":"2025100312591176000_11.8.e006913.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81341-0"},{"key":"2025100312591176000_11.8.e006913.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1214394109"},{"key":"2025100312591176000_11.8.e006913.21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2609"},{"key":"2025100312591176000_11.8.e006913.22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1221556","article-title":"The pattern of hMENA Isoforms is regulated by TGF-\u03921 in Pancreatic cancer and may predict patient outcome","volume":"5","author":"Melchionna","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100312591176000_11.8.e006913.23","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1038\/s41388-018-0364-3","article-title":"hMENA Isoforms impact NSCLC patient outcome through fibronectin\/\u03921 integrin axis","volume":"37","author":"Di Modugno","year":"2018","journal-title":"Oncogene"},{"key":"2025100312591176000_11.8.e006913.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00413-6"},{"key":"2025100312591176000_11.8.e006913.25","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.493"},{"key":"2025100312591176000_11.8.e006913.26","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1016\/j.cell.2022.08.011","article-title":"Actin cytoskeleton remodeling primes RIG-I-like receptor activation","volume":"185","author":"Acharya","year":"2022","journal-title":"Cell"},{"key":"2025100312591176000_11.8.e006913.27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M807547200"},{"key":"2025100312591176000_11.8.e006913.28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2025100312591176000_11.8.e006913.29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aae0477"},{"key":"2025100312591176000_11.8.e006913.30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207831"},{"key":"2025100312591176000_11.8.e006913.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0807301105"},{"key":"2025100312591176000_11.8.e006913.32","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-030212-183653"},{"key":"2025100312591176000_11.8.e006913.33","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.193"},{"key":"2025100312591176000_11.8.e006913.34","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.78"},{"key":"2025100312591176000_11.8.e006913.35","doi-asserted-by":"publisher","DOI":"10.1038\/ni1087"},{"key":"2025100312591176000_11.8.e006913.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02380-2"},{"key":"2025100312591176000_11.8.e006913.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.04.008"},{"key":"2025100312591176000_11.8.e006913.38","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191847","article-title":"Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis","volume":"217","author":"Donadon","year":"2020","journal-title":"J Exp Med"},{"key":"2025100312591176000_11.8.e006913.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02624.x"},{"key":"2025100312591176000_11.8.e006913.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.05.005"},{"key":"2025100312591176000_11.8.e006913.41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401088"},{"key":"2025100312591176000_11.8.e006913.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01141-9"},{"key":"2025100312591176000_11.8.e006913.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"2025100312591176000_11.8.e006913.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0"},{"key":"2025100312591176000_11.8.e006913.45","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112338","article-title":"Matrix stiffness regulates tumor cell Intravasation through expression and Esrp1-mediated alternative splicing of MENA","volume":"42","author":"Wang","year":"2023","journal-title":"Cell Rep"},{"key":"2025100312591176000_11.8.e006913.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.004"},{"key":"2025100312591176000_11.8.e006913.47","doi-asserted-by":"publisher","DOI":"10.1038\/nri3877"},{"key":"2025100312591176000_11.8.e006913.48","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.67"},{"key":"2025100312591176000_11.8.e006913.49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903487106"},{"key":"2025100312591176000_11.8.e006913.50","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0711"},{"key":"2025100312591176000_11.8.e006913.51","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37021-x","article-title":"Mena regulates the LINC complex to control actin\u2013nuclear Lamina associations, Trans-nuclear membrane signalling and cancer gene expression","volume":"14","author":"Li Mow Chee","year":"2023","journal-title":"Nat Commun"},{"key":"2025100312591176000_11.8.e006913.52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803093"},{"key":"2025100312591176000_11.8.e006913.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2012.01.008"},{"key":"2025100312591176000_11.8.e006913.54","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.02565"},{"key":"2025100312591176000_11.8.e006913.55","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ijc.32818","article-title":"High RIG-I expression in ovarian cancer Associates with an immune-escape signature and poor clinical outcome","volume":"146","author":"Wolf","year":"2020","journal-title":"Int J Cancer"},{"key":"2025100312591176000_11.8.e006913.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.06.031"},{"key":"2025100312591176000_11.8.e006913.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.05.005"},{"key":"2025100312591176000_11.8.e006913.58","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","article-title":"Tissue-resident Macrophages provide a pro-Tumorigenic niche to early NSCLC cells","volume":"595","author":"Casanova-Acebes","year":"2021","journal-title":"Nature"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-006913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:59:20Z","timestamp":1759521560000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-006913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,23]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/jitc-2023-006913"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-006913","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}